je.st
news
Tag: hepatitis
Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress 2014
2014-03-24 12:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Company to Initiate Phase 3 Clinical Development Program in Q2 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new Phase 2 data for its two investigational hepatitis C virus (HCV) treatments - MK-5172, an investigational HCV NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor are scheduled to be presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), also known as The International Liver Congress 2014. Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
international
present
annual
Healthier Patients May Have To Wait For Costly Hepatitis C Drugs
2014-03-12 22:45:08| Biotech - Topix.net
Expensive new drugs for hepatitis C may work better than older treatments, but their high cost undermines their value, a panel of experts said Monday during a daylong forum in San Francisco Monday.
Tags: wait
patients
drugs
costly
Mercks Investigational Hepatitis C Treatment Regimen MK-5172/MK-8742 Shows Robust Anti-HCV Activity in HIV/HCV Co-Infected Patients with HCV Genotype 1 Infection
2014-03-05 22:15:00| Merck.com - Research & Development News
Dateline City: BOSTON BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orIan McConnell, 908-423-3046orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: shows
activity
treatment
patients
Hepatitis C breakthrough drug Sovaldi promises high cure rates, costs
2014-03-05 10:12:31| Biotech - Topix.net
Kim Bossley, right, gives a goodbye hug to research nurse Andrea Herman on Monday at University of Colorado Hospital.
Insurers, Medicaid fear multibillion-dollar hepatitis C drug tab
2014-03-05 09:27:37| Apparel - Topix.net
U.S. health insurers are seeking help from state health officials to foot the bill for a new generation of hepatitis C treatments that could cost the nation $200 billion or more in the next five years.
Sites : [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] next »